Amid Covid vaccine success, BioNTech plans to return €2bn to shareholders

On Wednesday, the German company BioNTech promised to return around €2 billion to its shareholders via share buybucks and a special dividend. After its raging Covid-19 vaccine success in the year 2021 with the company Pfizer, the company had earned a lot of revenue. In one year, the company earned €18.9 billion in revenue alone. This marks a huge success compared to the revenue of 2020, which was €482.3 million.

The company has also exceeded the expectations of analysts' earnings forecasts. While experts estimated that the company's profit in the fourth quarter would be around €8.2 per share, BioNTech managed to secure €12.2 per share.

BioNTech has planned to deliver more than 2.4 billion vaccines this year, resulting in more than €17 billion. It also plans to buy €1.5 billion of its shares and intends to propose a special cash dividend of €2 a share in its yearly meeting.


New Ventures of the Maine-based company, BioNTech

• A new clinical trial for the Omicron variant of Covid-19 will expand. The new vaccine will provide boosted protection against the new variant. The data is said to be published in April.
• The company has also decided to increase the money spent on the research and development department by 50%, especially for the new mRNA technology-based drugs. The cost will now be around €1.5 billion.
• According to the co-founder and chief executive Ugur Sahin, the company will further increase its development towards mRNA-based immunotherapy, bi-specific antib

What is BioNTech company?

• BioNTech is a German biotech company. They launched the first COVID-19 vaccine in partnership with Pfizer.
• They are also working on RNA-based immunotherapies, cell therapies, and bi-specific antibodies to improve immunity and develop a new range of drugs in the future.
• In 2021, the company delivered around 2.6 billion doses of vaccine.

Why is BioNTech returning €2bn to shareholders?

In 2021 BioNTech and US-based pharmaceutical giant Pfizer made a huge profit. Reports show a net profit of 10.3 billion euros in 2021 and 15 million euros in 2020. After such a roaring success, BioNTech is planning to repurchase all its shares and introduce a special cash dividend of €2 a share.